Showing results (321-330 of 9,661) with videos related to
Sort By:
Pageof 967
Leukemia|October 21, 2021
AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcomePeng Li, Thomas White, Wei Xie, et al.Leukemia|April 3, 2022
Identification of a c-MYB-directed therapeutic for acute myeloid leukemiaKatherine Clesham, Vanessa Walf-Vorderwülbecke, Luca Gasparoli, et al.Leukemia|March 31, 2022
Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspectiveYoshihiro Hayashi, Yuka Harada, Hironori HaradaLeukemia|March 5, 2022
Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradicationSimona Moretti, Amal Kamal Abdel-Aziz, Elena Ceccacci, et al.Leukemia|March 30, 2022
RNAseqCNV: analysis of large-scale copy number variations from RNA-seq dataJan Bařinka, Zunsong Hu, Lu Wang, et al.Leukemia|May 31, 2019
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signalingMatthew Ho, Tianzeng Chen, Jiye Liu, et al.Leukemia|September 13, 2018
Downregulating Notch counteracts KrasGuangyao Kong, Xiaona You, Zhi Wen, et al.Leukemia|March 23, 1999
Polycythemia vera megakaryocytes but not megakaryocytes from normal controls and patients with smokers polyglobuly spontaneously express IL-6 and IL-6R and secrete IL-6C Wickenhauser, J Thiele, J Lorenzen, et al.Leukemia|March 23, 1999
MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1R Sood, A Talwar-Trikha, S R Chakrabarti, et al.Leukemia|March 23, 1999
Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosisC Posovszky, C Friesen, I Herr, et al.Pageof 967